Octreotide vs Pasireotide: What the Research Compares

What this comparison covers

Octreotide and pasireotide are prescription medicines in the somatostatin analogue class. Both bind somatostatin receptors, a receptor family whose structure, signalling and endocrine roles were summarised in a 2025 review of somatostatin and its receptors in endocrinology (PMID 39116368). This page describes what the published literature reports about each medicine and where the two appear together in the same study. It does not rank them, does not name one as preferable for any condition, and contains no dosing directions. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision.

Head to head evidence: what exists in the cited literature

Among the papers cited on this page, no named head-to-head randomized controlled trial report comparing octreotide directly against pasireotide is included. That is stated plainly rather than implied. Three cited sources do place the two molecules in the same analysis or the same patient narrative, and each is described below with its citation.

Network meta-analysis in acromegaly

A systematic literature review and network meta-analysis of pharmacologic therapies in acromegaly evaluated efficacy and safety across the available drug options, a method that pools direct and indirect comparisons from separate randomized trials into one framework (PMID 41773305). Network meta-analyses draw on trials that may not all have enrolled identical populations, so researchers who conduct them generally present the pooled estimates alongside caveats about heterogeneity, and the published report of that analysis should be read in full for its specific comparisons and confidence intervals (PMID 41773305).

Laboratory comparison in pituitary tumor cells

A 2016 study in The Journal of Endocrinology tested octreotide and pasireotide side by side in pituitary tumor cells in vitro and reported that the two compounds inhibited those cells in ways the authors described as both similar and dissimilar depending on the model examined (PMID 27587848). The study was a cell based experiment rather than a clinical trial, so its findings describe pharmacology in culture and not patient outcomes (PMID 27587848).

A case report describing both agents

A 2017 case report in Clinical Case Reports described the use of pasireotide and octreotide in severe late dumping syndrome (PMID 29026555). Single patient reports describe one clinical course and cannot establish comparative efficacy, a limitation that applies to that report as much as to any other case publication (PMID 29026555).

Class, mechanism and receptor profile

Somatostatin acts through a family of G protein coupled receptors, and the 2025 Endocrine Reviews article covered the structure and function of somatostatin and those receptors across endocrine tissues (PMID 39116368). Synthetic analogues differ in which receptor subtypes they engage most strongly, and the in vitro comparison of octreotide and pasireotide in pituitary tumor cells was designed around exactly that difference in receptor engagement (PMID 27587848).

Reviews of pasireotide in neuroendocrine tumors have discussed its broader somatostatin receptor binding profile as the rationale for studying it in settings where receptor subtype expression varies (PMID 29643113). A separate laboratory study reported that pasireotide inhibited catecholamine secretion in human pheochromocytoma cells, extending receptor pharmacology into a tumour type outside the pituitary (PMID 34637845).

Side by side: the separate evidence bases

Where each medicine has been studied

Acromegaly

A review of acromegaly described medical therapy as one component of care when surgery does not achieve biochemical control, placing somatostatin analogues within that sequence (PMID 23961470). A later review examined acromegaly that responded inadequately to octreotide and surveyed the challenges and the alternative strategies discussed in that literature (PMID 32440136). The 2026 network meta-analysis brought the pharmacologic options into a single efficacy and safety comparison (PMID 41773305).

Neuroendocrine tumours

A review of symptomatic neuroendocrine tumor syndromes summarised recent advances and controversies in symptom directed treatment, with somatostatin analogues central to that discussion (PMID 27635672). A dedicated review of pasireotide in neuroendocrine tumors surveyed the published trials and smaller studies of that agent in the same disease area (PMID 29643113). Preclinical work reported that pasireotide inhibited catecholamine secretion in human pheochromocytoma cells (PMID 34637845).

Pancreatic surgery and fistula prophylaxis

A systematic review and meta-analysis examined somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection (PMID 31980352). A separate meta-analysis of randomised controlled trials assessed prophylactic somatostatin therapy following pancreaticoduodenectomy (PMID 30798417). Both analyses pooled surgical trials rather than comparing the two specific analogues against one another as a primary objective (PMID 31980352, PMID 30798417).

Dumping syndrome after bariatric surgery

A 2025 review in Nutrients covered nutritional strategies and integrated pharmacological management for dumping syndrome after bariatric surgery, a setting in which somatostatin analogues appear in the treatment literature (PMID 41097200). The severe late dumping syndrome case report described both pasireotide and octreotide in one patient narrative (PMID 29026555).

Regulatory status

Both molecules are approved prescription medicines rather than investigational agents. Octreotide products have regulatory approval in the United States and the European Union for acromegaly and for control of symptoms associated with certain functional neuroendocrine tumours. Pasireotide products carry regulatory approval for Cushing disease and for acromegaly in patients for whom surgery is not an option or has not been curative. Approved indications, labelling and available formulations differ by country and by product, and prescribing information is the authoritative source for each. Decisions about whether either medicine is appropriate for a given person rest with a prescribing clinician.

Adverse Events: What Studies Report

Published safety discussions for this class concentrate on gastrointestinal symptoms, biliary and gallbladder findings and effects on glucose homeostasis. The 2026 systematic review and network meta-analysis of acromegaly therapies assessed safety alongside efficacy across the drug options it compared, and its published safety outcomes are the appropriate reference point for that disease setting (PMID 41773305).

The review of pasireotide in neuroendocrine tumors discussed tolerability alongside efficacy, including effects on glucose metabolism that researchers have tracked across the pasireotide literature (PMID 29643113). The review of acromegaly that responded inadequately to octreotide also addressed the trade offs reported when therapy is changed or escalated (PMID 32440136). In the surgical literature, the meta-analysis of prophylactic somatostatin therapy following pancreaticoduodenectomy pooled randomised trials that reported both outcome and complication data (PMID 30798417). The 2025 review of somatostatin receptor biology provides the mechanistic background for why receptor subtype engagement is relevant to the tolerability profile reported for different analogues (PMID 39116368).

How to read this comparison

• No named head-to-head randomized trial comparing the two medicines is included in the sources cited here, so the comparison rests on separate evidence bases plus one pooled analysis (PMID 41773305).
• Laboratory findings in pituitary tumor cells describe pharmacology in culture and do not predict clinical outcomes (PMID 27587848).
• Case reports describe individual clinical courses, not comparative efficacy (PMID 29026555).
• Reviews summarise other people's trials, and the primary trial reports they cite carry the detailed populations, endpoints and safety tables (PMID 27635672).

Related reading

• Octreotide: literature overview
• Pasireotide: literature overview

References

• Structure and Function of Somatostatin and Its Receptors in Endocrinology (Endocrine Reviews, 2025)
• Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro (The Journal of Endocrinology, 2016)
• Pasireotide and octreotide in the treatment of severe late dumping syndrome (Clinical Case Reports, 2017)
• Pasireotide in the treatment of neuroendocrine tumors: a review of the literature (Endocrine-Related Cancer, 2018)
• Acromegaly: Beyond surgery (Indian Journal of Endocrinology and Metabolism, 2013)
• Octreotide-Resistant Acromegaly: Challenges and Solutions (Therapeutics and Clinical Risk Management, 2020)
• Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies (Expert Opinion on Pharmacotherapy, 2016)
• Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells (Cancer Letters, 2022)
• Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection: a systematic review and meta-analysis (Pancreatology, 2020)
• The Use of Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials (World Journal of Surgery, 2019)
• Dumping Syndrome After Bariatric Surgery: Advanced Nutritional Perspectives and Integrated Pharmacological Management (Nutrients, 2025)